Drug Trial Radar · NCT06980532
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: May 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Apr 25, 2025
Primary completion
Dec 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Liu HuangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Glumetinib combined withFruquintinib in the treatment of MET amplification or protein overexpression in third-line unresectable metastatic colorectal cancer: evaluation of efficacy and safety
Conditions
- Metastatic Colorectal Cancer
Interventions
Glumetinib Combined with FruquintinibDrug
Fruquintinib: 3mg, po.qd, d1-14,q3w; Guemitinib: Grade 1:200mg, po, qd, q3w; Grade 2:250mg, po, qd, q3w; Phase I: The dose of Glumetinib (200 mg → 250 mg) is dynamically adjusted using the "3+3 dose-escalation rule" to determine the optimal dose of Fruquintinib. Phase II: The RP2D (Recommended Phase II Dose) of Glumetinib identified in Phase I is continued in combination with Fruquintinib.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended dose for Phase IITime frame: Up to approximately 18 Weeks
- Objective response rate(ORR)Time frame: Up to approximately 18 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.